DNTH
Dianthus Therapeutics Inc.
$41.45
+$1.06(+2.62%)
71
Overall
60
Value
83
Tech
--
Quality
Market Cap
$1.53B
Volume
834.78K
52W Range
$13.37 - $43.67
Target Price
$64.45
Company Overview
| Mkt Cap | $1.53B | Price | $41.45 |
| Volume | 834.78K | Change | +2.62% |
| P/E Ratio | -18.0 | Open | $40.39 |
| Revenue | $6.2M | Prev Close | $40.39 |
| Net Income | $-85.0M | 52W Range | $13.37 - $43.67 |
| Div Yield | N/A | Target | $64.45 |
| Overall | 71 | Value | 60 |
| Quality | -- | Technical | 83 |
No chart data available
About Dianthus Therapeutics Inc.
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. The company is developing DNTH103, a monoclonal antibody, which is in clinical-stage trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Latest News
Dianthus Therapeutics Reports Positive Phase 2 Results
TipRanks Auto-Generated Newsdesk•20 days ago
Dianthus Therapeutics Advances Phase 2 Study of DNTH103 for Neuropathy
TipRanks Clinical-Trials-Auto-Generated Newsdesk•a month ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | DNTH | $41.45 | +2.6% | 834.78K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Dianthus Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW